HomeAI · summaries
Storia in 3 fonti
Amgen hands in data package in hopes of FDA hearing for Tavneos defense
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the ANCA-associated vasculitis (AAV) drug it inherited in its $3.7 billion buyout of C | With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the ANCA-associated vasculitis (AAV) drug it inherited in its $3.7 billion buyout of ChemoCentryx.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis scored an FDA expansion for Tryngolza to become the…
- ·
Amgen hands in data package in hopes of FDA hearing for Tavneos defense
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the ANCA-associated vasculitis (AAV) drug it inherited in its $3.7…
